IMA 901

Drug Profile

IMA 901

Alternative Names: IMA-901; Renal cancer vaccine - immatics

Latest Information Update: 23 Sep 2015

Price : $50

At a glance

  • Originator immatics biotechnologies GmbH
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Renal cell carcinoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 17 Aug 2015 immatics Biotechnologies completes a phase III trial in Renal cell carcinoma (First-line therapy, Combination therapy, Late-stage disease) in France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, USA and United Kingdom (NCT01265901)
  • 21 Apr 2015 Phase-III development for Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease) is ongoing in France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, USA and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top